Healthy volunteers needed to unlock secrets of diabetes drug sitagliptin
NCT ID NCT06813014
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how healthy people without diabetes respond to sitagliptin, an FDA-approved diabetes medication. Researchers want to understand why some people's bodies process sugar differently after taking the drug. About 400 healthy Amish adults will take part in two clinic visits, each lasting about 5 hours, where they will drink a sugary drink and have blood tests.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 400 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Dec 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2032
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * • Age: \>18 years old * Members of Old Order Amish community in Lancaster, PA Exclusion Criteria: * • Pregnancy (reproductive age women will undergo pregnancy tests immediately before receiving the drug) * Diabetes: HbA1c \> 6.5% or fasting plasma glucose \>126 mg/dL * Estimated glomerular filtration rates (eGFR) \<60 mL/min/1.73 m2 * Anemia: hematocrit \< 35% * Thyroid status: TSH\<0.4 or TSH\>5.5 * ALT or AST in excess of 2X upper limit of normal * Drugs that in the physician's judgment would alter response to sitagliptin * Significant health issues that in the physician's judgment could increase the risk for participants.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Diabetes are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University of Maryland Amish Research Clinic
Lancaster, Pennsylvania, 17602, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gut bacteria may hold clues to dozens of diseases
- Heartbeat test aims to catch hidden nerve damage in diabetes
- Can Home-Delivered meals help control diabetes?
- New pill takes aim at blood sugar in diabetes
- Home c-peptide tests could reveal hidden insulin production in diabetes
- Brain scans may predict who is most at risk for dangerous low blood sugar